{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:11Z","timestamp":1772166311459,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15\u201345\u00a0years of age. There were no significant differences over time for any of the outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-02160-1","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T07:05:14Z","timestamp":1641452714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark"],"prefix":"10.1186","volume":"17","author":[{"given":"Troels","family":"Hvelplund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibi","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne Djernes","family":"Bird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malene","family":"Korsholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-6302","authenticated-orcid":false,"given":"Anette Dr\u00f8hse","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"issue":"1","key":"2160_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","volume":"245","author":"AD Kjeldsen","year":"1999","unstructured":"Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245(1):31\u20139.","journal-title":"J Intern Med"},{"issue":"1","key":"2160_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","volume":"14","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Orphanet J Rare Dis. 2019;14(1):256.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2160_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/j.1471-0528.2008.01786.x","volume":"115","author":"CL Shovlin","year":"2008","unstructured":"Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE, Sheppard MN. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler\u2013Weber\u2013Rendu syndrome): suggested approach for obstetric services. BJOG Int J Obstet Gynaecol. 2008;115(9):1108\u201315.","journal-title":"BJOG Int J Obstet Gynaecol."},{"key":"2160_CR4","unstructured":"European Reference Network for Rare Vascular Diseases. Missions & action plan. 2021. http:\/\/vascern.eu\/about-vascern\/#1461615813276-1deb4aba-5bc8."},{"issue":"1","key":"2160_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-018-0850-2","volume":"13","author":"CL Shovlin","year":"2018","unstructured":"Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, et al. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis. 2018;13(1):136.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2160_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"2160_CR7","unstructured":"Hospital OU. Research 2021. 19\/09\/2021. https:\/\/en.ouh.dk\/research\/open-odense-patient-data-explorative-network\/."},{"issue":"1","key":"2160_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu\u2013Osler\u2013Weber syndrome). Am J Med Genet. 2000;91(1):66\u20137.","journal-title":"Am J Med Genet"},{"issue":"1","key":"2160_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1378\/chest.06-2356","volume":"132","author":"K Zukotynski","year":"2007","unstructured":"Zukotynski K, Chan RP, Chow CM, Cohen JH, Faughnan ME. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest. 2007;132(1):18\u201323.","journal-title":"Chest"},{"issue":"5","key":"2160_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1378\/chest.08-1266","volume":"135","author":"MWF van Gent","year":"2009","unstructured":"van Gent MWF, Post MC, Snijder RJ, Swaans MJ, Plokker HWM, Westermann CJJ, et al. Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy? Chest. 2009;135(5):1288\u201392.","journal-title":"Chest"},{"issue":"9","key":"2160_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4329\/wjr.v2.i9.339","volume":"2","author":"PE Andersen","year":"2010","unstructured":"Andersen PE, Kjeldsen AD. Interventional treatment of pulmonary arteriovenous malformations. World J Radiol. 2010;2(9):339\u201344.","journal-title":"World J Radiol"},{"issue":"4","key":"2160_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/jmg.2005.035451","volume":"43","author":"TGW Letteboer","year":"2006","unstructured":"Letteboer TGW, Mager JJ, Snijder RJ, Koeleman BPC, Lindhout D, Ploos van Amstel JK, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet. 2006;43(4):371\u20137.","journal-title":"J Med Genet."},{"issue":"7","key":"2160_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/jmg.40.7.494","volume":"40","author":"SA Abdalla","year":"2003","unstructured":"Abdalla SA, Geisthoff UW, Bonneau D, Plauchu H, McDonald J, Kennedy S, et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet. 2003;40(7):494.","journal-title":"J Med Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02160-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T07:08:25Z","timestamp":1641452905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02160-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2160"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02160-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-948431\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients have given written consent that their health information may be used to clinical research. Use of the national HHT-database was approved by the Danish Data Protection Agency as of July 9th, 2015 (case number: 15\/10194) and the Danish Patient Safety Authority (case number: 3-3013-974\/1\/).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"No personal data included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}